Renal Denervation: Where We Stand After the FDA Panels
Experts’ thoughts on what defines a clinically meaningful reduction in blood pressure, roles of office-based and ambulatory blood pressure monitoring, ideal candidates for renal denervation and patient preference as a driver for the procedure, options that could meet the FDA's request for more data, and applying a team-based approach to screening and treatment.
With Ajay J. Kirtane, MD, SM; Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM; and Taisei Kobayashi, MD
